Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...

Cystic fibrosis is a life-threatening disease predominantly with respiratory symptoms. Most of the subjects with the disease harbor the F508del variant in the CFTR gene that causes the protein to ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

2 CF is caused by mutations in the CFTR gene. These mutations cause the CFTR protein to become dysfunctional, which leads to the development of sticky, thick mucus clogging the airways, which causes ...

Until recently, drug development efforts have emphasised therapies treating downstream signs and symptoms resulting from the underlying CF biological defect: reduced function of the CF transmembrane ...

Researchers trial inhalable gene therapy for cystic fibrosis, offering a potential breakthrough in treating the genetic lung ...

Sionna Therapeutics recently secured an initial public offering (IPO) of $191m on the Nasdaq stock exchange, signalling ...

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

Sionna Therapeutics found strong investor interest in its cystic fibrosis drugs, which could rival blockbuster Vertex ...

Boston, USA-based biotech Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...